Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

Sanofi reception

EASD 2013: Sanofi prepared for biosimilar threat to Lantus

Next generation insulin U300 set to launch at time of patent expiration

- PMLiVE

EASD 2013: Sanofi justifies decision to withdraw US filing for Lyxumia

Takes issue with FDA's narrow risk-benefit focus

- PMLiVE

GSK’s Revolade cleared for use in hepatitis C therapy

Adds to drug’s existing thrombocytopenia indication

- PMLiVE

EASD 2013: Pharma backs public/private diabetes research collaboration

Sanofi, Lilly and Boehringer support part of IMI Diabetes Platform

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

China flag thumb

Novartis’ Alcon unit diverted trial money for bribes, claims paper

21st Century Business Herald publishes more allegations of corruption in China

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links